skip to Main Content
Dr. Manuel Hidalgo

COMBATing Pancreatic Cancer

Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.

Black and white image of a cancer cell from under a microscope

Immunotherapy for Pancreatic Neuroendocrine Tumors

This trial is active, but no longer recruiting participants. Pancreatic neuroendocrine tumors (P-NETs) make up less than 5 percent of all pancreatic cancers. Unlike pancreatic ductal adenocarcinomas (PDAs), P-NETs originate in the hormone-making islet cells of the pancreas, respond to different treatments, and have an overall survival rate higher than PDAs. In a clinical trial,…

Dr. Luis Diaz, pancreatic cancer researcher

An Immunotherapy Game Changer

Immunotherapy with Keytruda (pembrolizumab) is approved for use in cancer patients with certain genetic defects in their tumors.

Back To Top